Showing results (101-110 of 202) with videos related to
Sort By:
Pageof 21
The Journal of Clinical Endocrinology and Metabolism|April 17, 2020
Thyroid Cancer Incidence in India Between 2006 and 2014 and Impact of OverdiagnosisChiara Panato, Salvatore Vaccarella, Luigino Dal Maso, et al.Breast Cancer Research and Treatment|August 23, 2024
Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancerAdam Brufsky, Marilyn L Kwan, Rickard Sandin, et al.Breast (Edinburgh, Scotland)|September 13, 2025
Palbociclib treatment in patients with HR+/HER2- advanced or metastatic breast cancer and visceral metastasis: A systematic literature reviewJulia C Radosa, Sara López-Tarruella Cobo, Johanna Dzieran, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 13, 2024
Health-related quality of life over chemotherapy course among individuals with early-stage breast cancer: the association of social determinants of health and neighborhood socioeconomic disadvantageKai-Lin You, Susan M Sereika, Catherine M Bender, et al.Future Oncology (London, England)|September 1, 2025
Finding the right tool for the specific task: navigating RWE tools and checklistsRichard Willke, Paul Cottu, Andrew Briggs, et al.Breast Cancer Research : BCR|October 18, 2011
Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancerRachel C Jankowitz, Kristine Cooper, Mark G Erlander, et al.Journal of Managed Care & Specialty Pharmacy|July 30, 2025
First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eligible populationLucille Sun, David L Veenstra, Adam Brufsky, et al.Breast Cancer Research and Treatment|April 8, 2014
Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancerDenise A Yardley, Peter A Kaufman, Adam Brufsky, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trialSusan L Greenspan, Adam Brufsky, Barry C Lembersky, et al.Urology|July 3, 2003
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-upWilliam K Oh, Judith Manola, Laurie Bittmann, et al.Pageof 21